An observational study found treatment with tofacitinib resulted in only a slightly higher rate of venous thromboembolism than tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Hardship Exception Applications Open for Clinicians Struggling with Quality Payment Program Reporting in 2020
The Centers for Medicare & Medicaid Services have provided the opportunity to apply for exceptions for the Performance Year (PY) 2020 Quality Payment Program Merit-Based Incentive Program (MIPS) program requirements. This will help clinicians finding PY2020 MIPS federal reporting difficult due to circumstances outside their control.
UHC Announces New Copay Accumulator Policy Affecting In-Office Treatments
Editor’s note Nov. 23, 2020: As of Nov. 12, 2020, UHC has delayed implementation of the policy discussed below. See “UnitedHealthcare Delays Copay Accumulator Policy.” UnitedHealthcare (UHC) announced that, as of Jan. 1, 2021, providers will be required to report the amount their patients receive in copay assistance for office-administered treatments. UHC will then use…
Find Solutions to Navigate Telerheumatology in Your Practice
Experts weigh in on sustaining telerheumatology as a viable practice tool by sharing its history, potential and regulatory outlook post-pandemic at ACR Convergence 2020.
ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues
Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts.
ACR Urges Commercial Payers to Cover Telemedicine Beyond the Public Health Emergency
In a letter sent to commercial payers, the ACR’s Insurance Subcommittee is advocating for continued coverage for telemedicine, including reimbursement parity, after the end of the declared public health emergency.
RheumPAC Hosts Rep. Kim Schrier, MD, for Legislative Update
RheumPAC donors attended a virtual legislative update and Q&A with former pediatrician Rep. Kim Schrier, MD (D-Wash.), to gain an insider’s view of current healthcare legislation.
Changes in ICD-10 for Sjögren’s Syndrome
A code change in the ICD-10 classification for Sjögren’s syndrome was approved by the ICD-10 Coordination and Maintenance Committee in July 2019 and becomes effective October 2020.
Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.
- « Previous Page
- 1
- …
- 180
- 181
- 182
- 183
- 184
- …
- 814
- Next Page »